PLX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 18, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 9, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Protalix BioTherapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Aug 12, 2026

8-K

Protalix BioTherapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 25, 2026

8-K

Protalix BioTherapeutics Corporate Update: Regulatory Approvals and Pipeline Progress

May 21, 2026

8-K

Protalix BioTherapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 13, 2026

8-K

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial Results and EU Approval for Elfabrio Dosing Regimen

Mar 18, 2026

8-K

European Commission Approves Every-Four-Weeks Dosing Regimen for Elfabrio® (pegunigalsidase alfa)

Mar 9, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

August 2025 ATM | Amount sold to date: $4,300,000

Aug 22, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mar 17, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Warrants amount: 489,938

Jul 7, 2023

424B5

ATM | Offering amount: $20,000,000

Feb 27, 2023

424B5

ATM | Offering amount: $20,000,000 | Amount sold to date: $90,777

May 2, 2022

424B5

ATM | Offering amount: $20,000,000

Jul 2, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 12, 2026

S-3/A

OFFERING

Aug 14, 2025

S-3

April 2025 SHELF EFFECTIVE, DATED 2025-08-22

Apr 28, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 1, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 11, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 14, 2022

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 17, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 28, 2023

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 18, 2023

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

HOLD Alapkezelo Zrt. (Filed by)

Oct 15, 2026

Schwartz Aharon (Reporting)

Sep 9, 2026

Naos Yaron (Reporting)

Sep 4, 2026

Melincoff Gwen A (Reporting)

Sep 4, 2026

Elze Christian (Reporting)

Sep 4, 2026

Boudes Pol F (Reporting)

Sep 4, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 25, 2025

CORRESP

Form CORRESP - Correspondence

Aug 20, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 30, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jun 30, 2022

CORRESP

Form CORRESP - Correspondence

Jun 29, 2022

LETTER

Form UPLOAD - SEC-generated letter

Jun 23, 2022

Protalix BioTherapeutics, Inc. PLX · SEC Filings